title: Inflammatory mediators in morbidly obese subjects: associations with glucose abnormalities and changes after oral glucose.
abstract: OBJECTIVE
  To explore inflammatory mediators in morbidly obese (MO) subjects with various categories of glucose tolerance and to study the changes in these mediators after an oral glucose load.
  
  
  METHODS
  Cross-sectional and experimental study.
  
  
  METHODS
  A total of 144 MO subjects were classified into three categories: normal glucose tolerance (NGT); pre-diabetes; and new onset diabetes mellitus (NODM) were included, as were 27 normal weight normoglycemic controls. Serum osteoprotegerin (OPG), visfatin, leptin, adiponectin, interleukin-1 receptor antagonist (IL-1Ra), and C-reactive protein (CRP) were analyzed during an oral glucose tolerance test (OGTT).
  
  
  RESULTS
  Fasting levels of leptin and IL-1Ra were consistently higher in obese persons (P<0.001 and P<0.05). MO subjects with NGT had higher CRP levels (P<0.001) and lower adiponectin levels (P<0.05) compared to controls. Yet when compared with MO subjects with NODM, those with NGT had lower CRP levels and higher adiponectin levels (both P<0.05). Baseline OPG and visfatin levels did not differ between the groups (P=0.326 and P=0.198). During OGTT, OPG levels decreased (P<0.001) and visfatin levels increased transiently (P=0.018). The response in OPG and visfatin did not differ between the groups (P=0.690 and P=0.170). There were minor changes in adiponectin and leptin levels.
  
  
  CONCLUSIONS
  Morbid obesity and glucose intolerance were associated with lower adiponectin levels and higher CRP levels, thus supporting a relationship between obesity, glucose homeostasis, and inflammation. Oral glucose suppressed OPG levels and transiently enhanced visfatin levels independent of obesity and glucose tolerance status, indicating that glucose may be involved in the acute regulation of these proteins.
authors: Morbid Obesity Center, Vestfold Hospital Trust, PO Box 2168, 3103 Tønsberg, Norway. dag.hofso@siv.no
authors: Dag
authors: D
authors: Hofsø
authors: Thor
authors: T
authors: Ueland
authors: Helle
authors: H
authors: Hager
authors: Trond
authors: T
authors: Jenssen
authors: Jens
authors: J
authors: Bollerslev
authors: Kristin
authors: K
authors: Godang
authors: Pål
authors: P
authors: Aukrust
authors: Jo
authors: J
authors: Røislien
authors: Jøran
authors: J
authors: Hjelmesaeth
mesh_terms: D054392:Adipokines / Q000097:blood; D000328:Adult; D016207:Cytokines / Q000097:blood; D005260:Female; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology*; D044882:Glucose Metabolism Disorders / Q000097:blood / Q000150:complications* / Q000378:metabolism; D005951:Glucose Tolerance Test; D006801:Humans; D018836:Inflammation Mediators / Q000097:blood*; D008297:Male; D008875:Middle Aged; D054409:Nicotinamide Phosphoribosyltransferase / Q000097:blood; D009767:Obesity, Morbid / Q000097:blood* / Q000150:complications* / Q000378:metabolism; D053244:Osteoprotegerin / Q000097:blood
chemical_list: D054392:Adipokines; D016207:Cytokines; D018836:Inflammation Mediators; D053244:Osteoprotegerin; C506030:TNFRSF11B protein, human; D054409:Nicotinamide Phosphoribosyltransferase; C085455:nicotinamide phosphoribosyltransferase, human; D005947:Glucose